BridgeBio Pharma (BBIO) PT Raised to $91 at Goldman Sachs, Following Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $74.95 +5.97%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $91.00 (from $83.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on BridgeBio Pharma (BBIO)
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
- Boot Barn (BOOT) PT Lowered to $175 at Jefferies, 'We recommend buying BOOT'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
